Skip to main content
      Dr. Sun et al. from Duke University presented abstract POS0692 during one of the poster sessions entitled, “Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers.” They evaluated differences in self-reported medication adherence and reasons for nonadherence across Type 1 & 2 SLE classification groups, with a prespecified focus on comparing
      Renal Biopsies in SLE
      #TYK2i #deucravacitinib
      #RCT in #SLE
      LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post

      Janet Pope Janetbirdope

      2 months ago
      #TYK2i #deucravacitinib #RCT in #SLE LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts #POS0695 #EULAR2026 @RheumNow https://t.co/vtrMYrFmJ9
      Can you step down #belimumab
      In well controlled #SLE without flaring?

      N=22 on #BEL eligible of 152
      Able to taper if
      RE

      Janet Pope Janetbirdope

      2 months ago
      Can you step down #belimumab In well controlled #SLE without flaring? N=22 on #BEL eligible of 152 Able to taper if REM >6/12 No #steroids Normal C3,C4 Neg #antiDNA Remission maintained in pts who reduced dose 6/22 didn’t flare OFF Rx ✅nice #POS1052 #EULAR2026 @RheumNow https://t.co/IEyfRtTGfT
      #EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE
      This study evaluated the risk of flares after sustained drug-free rem in SLE.
      % of pts w/ reported flares w/n yrs in re

      sheila RHEUMarampa

      2 months ago
      This study evaluated the risk of flares after sustained drug-free rem in SLE. % of pts w/ reported flares w/n yrs in rem: 48.6% at 2yrs 42.3% at 3yrs 35.2% at 5 yrs Mucocut, msk, renal & immuno - ⬆️affected domain Reassess pts regularly. POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh
      What’s new with the 2026 update of reco for vax in AIIRD?
      Vaccinate as soon as possible
      Non-live vaccines are safe
      Ho

      sheila RHEUMarampa

      2 months ago
      What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome
      He emphasizes the inportanc

      sheila RHEUMarampa

      2 months ago
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW
      Do u screen your SLE pts for OP?
      In this real-world multicenter study, SLE pts who were likely to be tested for BMD wer

      sheila RHEUMarampa

      2 months ago
      Do u screen your SLE pts for OP? In this real-world multicenter study, SLE pts who were likely to be tested for BMD were older, had MSK s/sxs, sSJg & longer GC exposure. RFs for OP: LN, higher dse. activity, longer GC use, high cumulative GC dose POS1372 @RheumNow #EULAR2026 https://t.co/pAxhOPGGYs
      ×